Literature DB >> 21087818

DNA methylation in thoracic neoplasms.

Chen Chen1, Ni Yin, Bangliang Yin, Qianjin Lu.   

Abstract

Thoracic neoplasms, which include lung cancers, esophageal carcinoma, and thymic epithelial tumors, are the leading causes of tumor-related death and a major health concern worldwide. The development of neoplasms is a multistep process involving both genetic and epigenetic alterations. A growing body of research provides evidence that aberrant DNA methylation, including DNA hypermethylation in promoter regions, global DNA hypomethylation and the overexpression of DNA methyltransferases, plays an important role in tumorigenesis. In this review, we summarize published observations of methylation pattern disruptions in thoracic tumors, and discuss how these abnormalities contribute to the development of cancers. We review recent findings showing that suppressing the activity of the DNA methylating enzymes DNMTs can have potent anti-cancer effects, and discuss the possibility of developing novel therapies for thoracic tumors based on DNMT inhibition. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21087818     DOI: 10.1016/j.canlet.2010.10.017

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

Review 1.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

2.  Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.

Authors:  Teresa Bellissimo; Federica Ganci; Enzo Gallo; Andrea Sacconi; Claudia Tito; Luciana De Angelis; Claudio Pulito; Silvia Masciarelli; Daniele Diso; Marco Anile; Vincenzo Petrozza; Felice Giangaspero; Edoardo Pescarmona; Francesco Facciolo; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Mol Cancer       Date:  2017-05-10       Impact factor: 27.401

Review 3.  Beyond the genome: epigenetic mechanisms in lung remodeling.

Authors:  James S Hagood
Journal:  Physiology (Bethesda)       Date:  2014-05

4.  DNA methylation profile and expression of surfactant protein A2 gene in lung cancer.

Authors:  Melissa Grageda; Patricia Silveyra; Neal J Thomas; Susan L DiAngelo; Joanna Floros
Journal:  Exp Lung Res       Date:  2014-12-16       Impact factor: 2.459

5.  The Studies of Prognostic Factors and the Genetic Polymorphism of Methylenetetrahydrofolate Reductase C667T in Thymic Epithelial Tumors.

Authors:  Miaolong Yan; Jiayuan Wu; Min Xue; Juanfen Mo; Li Zheng; Jun Zhang; Zhenzhen Gao; Yi Bao
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

6.  Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines.

Authors:  Alice Pasini; Giulia Paganelli; Anna Tesei; Wainer Zoli; Emanuele Giordano; Daniele Calistri
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

7.  Prognostic value of Iroquois homeobox 1 methylation in non-small cell lung cancers.

Authors:  Ji Yun Lee; Won Kee Lee; Jae Yong Park; Dong Sun Kim
Journal:  Genes Genomics       Date:  2020-03-21       Impact factor: 1.839

8.  Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer.

Authors:  Meredith A Tennis; Michelle M Vanscoyk; Lora A Wilson; Nicole Kelley; Robert A Winn
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

9.  Overexpression of DNA damage-induced 45 α gene contributes to esophageal squamous cell cancer by promoter hypomethylation.

Authors:  Bao xiang Wang; Bang Liang Yin; Bin He; Chen Chen; Ming Zhao; Wei xing Zhang; Zhen Kun Xia; Yi zhi Pan; Jing qun Tang; Xin min Zhou; Ni Yin
Journal:  J Exp Clin Cancer Res       Date:  2012-02-08

10.  Association of the DNMT3B -579G>T polymorphism with risk of thymomas in patients with myasthenia gravis.

Authors:  Fabio Coppedè; Roberta Ricciardi; Maria Denaro; Anna De Rosa; Carlo Provenzano; Emanuela Bartoccioni; Angelo Baggiani; Marco Lucchi; Alfredo Mussi; Lucia Migliore
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.